NCT03495479View on ClinicalTrials.gov

Aneustat Treatment of Localized Prostate Cancer Under Active Surveillance

WithdrawnOBSERVATIONAL
0
Timeline

Start Date

January 31, 2025

Primary Completion Date

January 31, 2028

Study Completion Date

January 31, 2029

Conditions
Prostate Cancer
Interventions
DRUG

OMN54

Twice daily, self administered, oral dosing of OMN54. A daily diary log will be prepared by each participant and reviewed by the Investigator.

Sponsors
All Listed Sponsors
collaborator

Vancouver Prostate Centre

OTHER

lead

Omnitura Therapeutics, Inc.

INDUSTRY

NCT03495479 - Aneustat Treatment of Localized Prostate Cancer Under Active Surveillance | Biotech Hunter | Biotech Hunter